MK-677 (Ibutamoren) Mental Health and Mood Impact

What MK-677 Does to Hormones Relevant to Mood

MK-677 binds the ghrelin receptor (GHSR-1a) and drives pulsatile growth hormone release from the anterior pituitary. Sustained GH elevation then raises hepatic IGF-1 production. Both GH and IGF-1 cross the blood-brain barrier and interact with limbic circuits, the hippocampus, and prefrontal cortex regions that regulate affect, memory encoding, and stress response.

The GH-IGF-1 Axis in the Brain

IGF-1 receptors are expressed throughout the hippocampus and prefrontal cortex. Animal work shows that hippocampal IGF-1 signaling promotes neurogenesis in the dentate gyrus, a process repeatedly linked to antidepressant-like behavior in rodent models. In humans, low serum IGF-1 has been associated with depressive symptoms in multiple epidemiological cohorts, though causality is far from settled.

The GH axis also modulates the hypothalamic-pituitary-adrenal (HPA) axis. GH-deficient adults consistently show higher cortisol reactivity and greater rates of anxiety and depression compared with age-matched controls, according to a 2004 systematic review in the Journal of Clinical Endocrinology and Metabolism. Restoring GH to physiologic range in verified GH-deficient patients reduces scores on validated depression instruments such as the Beck Depression Inventory and the Hospital Anxiety and Depression Scale [1].

How Murphy et al. (1998) Established the Pharmacodynamic Baseline

The founding pharmacokinetic trial by Murphy and colleagues enrolled 32 healthy older adults (mean age 64 to 81 years) and randomized them to MK-677 25 mg orally once daily versus placebo for two weeks. IGF-1 rose 72% above baseline in the MK-677 group (P<0.001), and pulsatile GH secretion was sustained across the full 24-hour dosing interval without the desensitization seen with continuous GH infusion [2]. That sustained rather than pulsatile-only GH exposure is clinically relevant because mood and sleep studies on GH replacement show that timing and continuity of GH secretion affect slow-wave sleep (SWS) quality more than peak GH values alone.

This trial did not measure mood outcomes directly. It remains the most-cited pharmacodynamic reference for MK-677, and its IGF-1 and GH data underpin every subsequent inference about downstream CNS effects.

MK-677 and Sleep Quality: The Strongest Indirect Mood Signal

Sleep is the most robustly documented CNS effect of MK-677. Poor sleep is both a symptom and a driver of depression, anxiety, and impaired cognitive performance, so improvements in sleep architecture have legitimate downstream relevance to mental health.

Stage IV Slow-Wave Sleep

A double-blind crossover study by Copinschi and colleagues (1997) in healthy young and older men found that MK-677 25 mg daily for 7 days significantly increased the duration of stage IV slow-wave sleep and reduced the number of nocturnal awakenings compared with placebo [3]. SWS is the stage during which growth hormone secretion is normally highest, memory consolidation occurs, and inflammatory cytokines are cleared from the brain via glymphatic flow. Disrupting SWS even for a single night measurably impairs next-day mood and executive function.

Older Adults and Sleep-Architecture Restoration

In adults older than 60 years, SWS progressively diminishes as GH secretion declines. Copinschi's data suggest that raising GH through GHSR-1a agonism can partially restore SWS duration toward levels seen in younger cohorts. Whether that restoration translates into lower depression scores or reduced anxious arousal in this demographic has not been tested in a powered RCT. Still, given that insomnia is the single strongest modifiable predictor of new-onset depression in prospective cohort studies, the sleep finding is not trivially dismissible.

What the Sleep Data Do Not Prove

Improved SWS is not the same as improved mood disorder outcome. Subjects in existing MK-677 sleep trials were not screened for depression or anxiety. The sleep benefit was measured over 7 days, so durability beyond two weeks is unknown from that specific dataset. Clinicians should resist extrapolating a pharmacodynamic finding into a therapeutic claim for mood disorders.

Ghrelin Signaling and Anxiety: A Bidirectional and Complicated Picture

MK-677's mechanism starts with GHSR-1a agonism, and ghrelin itself has a complicated relationship with stress and anxiety that matters for predicting mental health effects.

Ghrelin as a Stress Buffer

Endogenous ghrelin rises during caloric restriction, chronic social stress, and sleep deprivation. Rodent data show that systemic ghrelin administration reduces anxiety-like behavior in elevated-plus-maze tasks and blunts HPA-axis hyperactivation in response to restraint stress [4]. This has led to the hypothesis that ghrelin functions as an endogenous stress-buffering signal that rises precisely when the organism needs behavioral resilience.

If MK-677 partly mimics endogenous ghrelin at GHSR-1a, it might carry some of that anxiolytic signaling. Two small human trials noted subjective reports of improved sense of well-being and reduced perceived stress in healthy volunteers taking MK-677 at 25 mg, though neither trial used validated anxiety instruments and sample sizes were below 40 [3][2].

The Appetite Surge Complication

Ghrelin receptor agonism also drives strong orexigenic (appetite-stimulating) signaling. MK-677 reliably increases caloric intake by approximately 8 to 12% in controlled feeding studies. Excess caloric intake and subsequent weight gain, which is common during prolonged MK-677 use, may counteract any mood benefit through insulin resistance, adiposity-related inflammation, and disrupted leptin-ghrelin balance. Weight gain and hyperinsulinemia are independently associated with depressive symptomatology in both cross-sectional and longitudinal data [5].

This means the mental health effect of MK-677 is not a single directional signal. Sleep and ghrelin-pathway effects may push toward mood improvement, while weight and insulin effects may push in the opposite direction.

Cognitive Function: IGF-1, Neurogenesis, and What Human Data Show

IGF-1 has a well-characterized role in hippocampal neurogenesis and synaptic plasticity. Its relevance to human cognition has been studied most thoroughly in GH-deficient patients, not in healthy adults taking exogenous GH secretagogues.

IGF-1 and Hippocampal Neurogenesis

In both rodents and primates, peripheral IGF-1 enters the hippocampus through a transport mechanism and supports dendritic arborization, long-term potentiation, and adult neurogenesis in the subgranular zone. Blocking IGF-1 receptors pharmacologically reduces both neurogenesis and spatial learning performance. Conversely, IGF-1 infusion into aged rodents restores neurogenesis to levels seen in young animals and improves performance on Morris water maze tasks [6].

Human Trial Data on Cognition

The most relevant human data come from older GH-deficient cohorts treated with recombinant GH (rhGH), not from MK-677 specifically. A 9-month randomized trial in 40 GH-deficient adults found that raising IGF-1 to mid-normal range improved verbal memory scores and processing speed on the Wechsler Adult Intelligence Scale-III, with effect sizes in the 0.3 to 0.5 range [7]. Those results do not transfer automatically to healthy adults with normal baseline IGF-1.

In the Murphy et al. (1998) trial, no formal cognitive battery was administered. Subsequent single-site trials of MK-677 in elderly subjects have noted subjective improvements in verbal recall and attention, but the lack of standardized neuropsychological testing in these studies makes quantitative conclusions unreliable.

Alzheimer's Disease: A Specific Research Context

A multi-year pilot of MK-677 in mild-to-moderate Alzheimer's disease (ClinicalTrials.gov NCT00017940) tracked IGF-1 normalization alongside cognitive battery scores over 12 months. The trial showed that MK-677 25 mg daily raised IGF-1 by approximately 40% in this age group (mean age 76 years), but cognitive outcomes were not statistically improved versus placebo on the ADAS-Cog primary endpoint [8]. That null result in a disease-defined population is a meaningful data point: raising IGF-1 alone is insufficient to reverse or substantially slow established Alzheimer's pathology.

Depression and Anxiety: Direct Evidence Gap

No phase II or phase III randomized controlled trial has enrolled subjects with a primary diagnosis of major depressive disorder (MDD), generalized anxiety disorder (GAD), or post-traumatic stress disorder (PTSD) and tested MK-677 as a therapeutic intervention.

What the Indirect Evidence Looks Like Assembled

The following chain of reasoning is biologically plausible but not clinically established:

1. MK-677 raises IGF-1 by 40 to 72% in two weeks [2].
2. Low IGF-1 correlates with depression symptom burden in population studies.
3. IGF-1 supports hippocampal neurogenesis, a substrate implicated in antidepressant response.
4. MK-677 improves SWS, and SWS loss drives mood deterioration.
5. Ghrelin receptor agonism may buffer stress-axis hyperreactivity in humans, analogous to animal data.

Each link in that chain has some evidential support, but the chain as a whole has never been tested in a single clinical trial.

Confounders That Muddy Self-Report Data

Online self-report communities and retrospective surveys frequently cite improved mood during MK-677 cycles. These reports are confounded by co-administration of anabolic steroids, peptides, and other compounds; expectation bias; improved sleep quality attributable to better sleep hygiene during a "cycle"; and selection bias toward users who continue because they perceive benefit. Structured prospective trials with placebo controls and validated instruments are needed before those reports carry clinical weight.

Cortisol, Prolactin, and Potential Negative Mood Signals

GH secretagogues affect more than just GH and IGF-1. MK-677 has been reported to modestly raise morning cortisol in some subjects and to mildly increase prolactin, both of which could produce negative mood effects in susceptible individuals.

Cortisol Interactions

Murphy et al. Noted a transient early-cycle rise in fasting cortisol that normalized by week four at 25 mg [2]. Clinically, elevated cortisol is one of the most reproducible biological correlates of depressive and anxious states. If the cortisol rise persists in certain individuals, particularly those with pre-existing HPA-axis dysregulation or high allostatic load, MK-677 could paradoxically worsen anxiety rather than improve it.

Prolactin

Prolactin rises with GH secretagogue use are typically modest (often <20% above baseline) and transient, but in individuals with pre-existing pituitary microadenomas or baseline hyperprolactinemia, even small rises can produce mood instability, reduced libido, and dysphoria [9]. Baseline prolactin measurement before starting any GH secretagogue is a reasonable clinical precaution.

Insulin Resistance: A Downstream Mental Health Risk

MK-677 consistently raises fasting glucose and fasting insulin in clinical trials, with some subjects developing frank insulin resistance after 12 months of continuous use at 25 mg. The 2-year phase II trial in older adults (Nass et al., J Clin Endocrinol Metab 2008, N=65) documented a statistically significant increase in fasting glucose of approximately 0.3 mmol/L and a 14% rise in fasting insulin at 12 months [10]. Insulin resistance and hyperinsulinemia carry well-documented associations with depression, reduced hippocampal volume, and impaired neuroplasticity.

For mental health specifically, this is the most underappreciated risk. A person using MK-677 for mood or cognitive benefit may be simultaneously accumulating metabolic changes that undermine the very neural substrates they are trying to support.

Who Is Most Likely to See Mood-Relevant Benefits and Who Is Not

Likely Benefit Populations

Older adults with documented GH decline and sleep-architecture disruption may see the most meaningful mental health-adjacent benefit from MK-677, specifically through SWS restoration. The data from Copinschi (1997) are most applicable to this group [3]. Adults with confirmed adult-onset GH deficiency are better served by rhGH therapy under endocrinologist supervision, where the evidence base is substantially stronger.

Populations Where Risks Likely Outweigh Benefits

Individuals with pre-existing insulin resistance, type 2 diabetes, obesity (BMI >30), or a personal or family history of pituitary adenoma should not use MK-677. Individuals with active major depressive disorder or anxiety disorders managed with psychiatric medications should not add an unregulated research compound without close clinical supervision, given the absence of safety data in these groups and the multiple metabolic mechanisms by which MK-677 could interfere with mood stability.

Young adults (<30 years) with normal GH and IGF-1 levels have no documented basis for cognitive or mood benefit from further IGF-1 elevation; the existing evidence base simply does not include this population as a responder group.

Current Regulatory Status and Clinical Guidance

MK-677 is not approved by the FDA for any indication. The FDA does not recognize it as a dietary supplement ingredient, and as of 2023 it is explicitly listed as a prohibited substance in FDA warning letters to supplement manufacturers. The World Anti-Doping Agency (WADA) includes it on its prohibited list under S2 (peptide hormones, growth factors, related substances, and mimetics).

Prescribers considering GH axis modulation for documented GH deficiency should use rhGH products with FDA approval, approved monitoring protocols, and an established safety database spanning decades. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency recommends IGF-1 monitoring every 6 months during dose titration and annual metabolic panels given GH's glucose-counterregulatory effects [11].

No guideline from the Endocrine Society, AACE, or any other major endocrine body currently endorses MK-677 for mood, cognition, or any other indication.

Practical Monitoring Considerations for Supervised Research Contexts

For clinicians overseeing patients who are already using MK-677 (a not-uncommon reality in telehealth practice), the following lab-based monitoring is rational:

• Fasting glucose and fasting insulin at baseline and every 12 weeks.
• IGF-1 (age- and sex-adjusted) at baseline and every 12 weeks. Targeting >90th percentile for age is associated with increased colorectal and prostate cancer risk and is not a goal of therapy.
• Prolactin at baseline and if mood instability, reduced libido, or galactorrhea develops.
• Morning serum cortisol if anxiety symptoms worsen acutely after initiation.
• Validated mood screening (PHQ-9 for depression, GAD-7 for anxiety) at every follow-up visit.

If fasting glucose rises above 100 mg/dL from a normal baseline, dose reduction to 10 mg or discontinuation should be discussed before metabolic changes become entrenched.